Evidence map›Paper›PMID 41808412›Full record

Observational studyAnnals of clinical and translational neurology2026

Low Incidence of Relapses After Vaccination in Anti-Aquaporin-4 Antibody-Positive NMOSD.

Sean J Pittock, Jin Nakahara, Becky Parks, Kerstin Allen, Sami Fam

2 registry-linked trialsAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01892345 phase3terminatednot on this map

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)

TypeinterventionalSponsorAlexion Pharmaceuticals, Inc.Ran2014 to 2018Enrolled143ConditionsNeuromyelitis Optica, Neuromyelitis Optica Spectrum DisorderArmsEculizumab, Placebo
NCT04201262 phase3completednot on this map

A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

TypeinterventionalSponsorAlexion Pharmaceuticals, Inc.Ran2019 to 2024Enrolled58ConditionsNeuromyelitis Optica, Neuromyelitis Optica Spectrum DisorderArmsRavulizumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sean J PittockDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-6140-5584
Jin NakaharaDepartment of Neurology, Keio University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5858-0998
Becky ParksAlexion, AstraZeneca Rare Disease, Clinical Development, Boston, Massachusetts, USA.
Kerstin AllenAlexion, AstraZeneca Rare Disease, Biostatistics, Boston, Massachusetts, USA.
Sami FamAlexion, AstraZeneca Rare Disease, Global Medical Affairs Neurology, Boston, Massachusetts, USA.ORCID https://orcid.org/0009-0009-7221-6365

Funding

Alexion, AstraZeneca Rare Disease
6 · The paper itself

Abstract

Patients with neuromyelitis optica spectrum disorder (NMOSD) may experience increased signs and symptoms of their underlying disease when vaccinated against meningococcal disease before receiving complement component 5 inhibitor therapies. This retrospective analysis indicated an overall low relapse incidence (mean [range], 3.3% [0.7%-10.6%]) of physician-reported relapses occurring within 4 weeks of meningococcal vaccination in those screened in CHAMPION-NMOSD (NCT04201262), randomized to eculizumab or placebo in PREVENT (NCT01892345), and from the Japanese postmarketing surveillance of eculizumab in patients with anti-aquaporin-4 antibody-positive NMOSD. Further studies are needed to determine if postvaccination relapses are attributable to vaccination or inherent relapse risk among these patients.

Indexed as

Antibodies, Monoclonal, HumanizedAquaporin 4AutoantibodiesMeningococcal VaccinesNeuromyelitis OpticaVaccinationAdultFemaleHumansIncidenceMaleMiddle AgedRandomized Controlled Trials as TopicRecurrenceRetrospective StudiesAntibodies, Monoclonal, HumanizedAQP4 protein, humanAquaporin 4AutoantibodieseculizumabMeningococcal Vaccinesanti‐aquaporin‐4 antibody‐positivemeningococcal vaccinationneuromyelitis optica spectrum disorderrelapses

Identifiers

PMID41808412
PMCPMC13358545

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.